The emerging role of CXC chemokines and their receptors in cancer

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 853-867

  Vinader, Victoria ^a   Afarinkia, Kamyar ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; A2,5 THIADIAZOLE 1 OXIDE; ADAM 10; ALPHA CHEMOKINE; AMG487; AZ 10397767; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; CTCE 9908; DF 2162; GSK812397; JANUS KINASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MSX 122; NAVARIXIN; PLERIXAFOR; REPARIXIN; SB 265610; SB 332235; SB 332255; SB 468477; SB 656933; SCH 479833; SCH 563705; TN14003; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VASCULOTROPIN; WO2006088919A2; WO2007002742A2; WO2007084728A2; WO2007115231A2;

ANGIOGENESIS; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION; COLON CANCER; DRUG EFFECT; DRUG TARGETING; HUMAN; LIVER METASTASIS; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TUMOR CELL; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINES, CXC; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CXCR; SMALL MOLECULE LIBRARIES;

EID: 84861071963     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.48     Document Type: Review

References (243)

1. Acosta JC, Gil J. A Role for CXCR2 in senescence, but what about in cancer? Cancer Res. 69(6), 2167-2170 (2009
2. Acosta J C, O'Loghlen A, Banito A, Raguz S, Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle 7(19), 2956-2959 (2008
3. Acosta JC, O'Loghlen A, Banito A et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133(6), 1006-1018 (2008
4. Gosselin RD, Dansereau MA, Pohl M et al. Chemokine network in the nervous system: A new target for pain relief. Curr. Med. Chem. 15(27), 2866-2875 (2008
5. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res. Rev. 60(1), 125-134 (2008
6. White F A, Feldman P, Miller RJ. Chemokine signaling and the management of neuropathic pain. Mol. Interv. 9(4), 188-195 (2009
7. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease Exp. Cell Res. 317(5), 575-589 (2011
8. Lazennec G, Richmond A. Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol. Med. 16(3), 133-144 (2010
9. Charo IF, Ransohoff RM. Mechanisms of disease - the many roles of chemokines and chemokine receptors in inflammation. New Engl. J. Med. 354(6), 610-621 (2006
10. Donnelly LE, Barnes PJ. Chemokine receptor CXCR2 antagonism to prevent airways inflammation. Drugs Fut. 36(6), 465-472 (2011
11. Kalinowska A, Losy J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin. Investig. Drugs 17(9), 1267-1279 (2008
12. Bestebroer J, de Haas CJC, van Strijp JAG. How microorganisms avoid phagocyte attraction. Fems Microbiol. Rev. 34(3), 395-414 (2010
13. Wu YT, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog. 5(12), e1000520 (2009
14. Balkwil, F. Cancer and the chemokine network. Nat. Rev. Cancer 4(7), 540-550 (2004
15. Zlotnik A. Chemokines and cancer. Int. J. Cancer 119(9), 2026-2029 (2006
16. Raman D, Baugher PJ, Thu Y M, Richmond A. Role of chemokines in tumor growth Cancer Lett. 256(2), 137-165 (2007
17. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109(12), 2392-2404 (2007
18. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21(1), 27-39 (2010
19. Homey B, Müller A, Zlotnik A. Chemokines: Agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2, 175-184 (2002
20. Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 1(1), 109-127 (2009
21. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824), 50-56 (2000
22. Richmond A. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res. 23(3), 312-313 (2010
23. Krieg C, Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semen. Cancer Biol. 19(2), 76-83 (2009
24. Pivarcsi A, Muller A, Hippe A et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl Acad. Sci. USA 104(48), 19055-19060 (2007
25. Wang B, Hendricks DT, Wamunyokoli F, Parker IMA. Growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 66, 3071-3077 (2006
26. Huang J T, Yao JL, Zhang L et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am. J. Pathol. 166(6), 1807-1815 (2005
27. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Brit. J. Cancer. 91(11), 1970-1976 (2004
28. Gabellini C, Trisciuoglio D, Desideri M et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer. 45(1), 2618-2627 (2009
29. Wang PA, Redmond J H, Cronin HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 10, 225 (2010
30. Shi CL Yu CH, Zhang Y, Zhao D, Chang XH, Wang W-H. Monocyte chemoattractant protein-1 modulates invasion and apoptosis of PC-3M prostate cancer cells via regulating expression of VEGF, MMP9 and caspase-3. Asian Pac. J. Cancer Prev. 12(2), 555-559 (2011
31. Van-Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukocyte Biol. 82(6), 1375-1381 (2007
32. Hatfield KJ, Reikvam H. Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr. Med. Chem. 17(36), 4448-4461 (2010
33. Wilson C, Purcell C, Seaton A et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-k B transcription and evasion of apoptosis. J. Pharmacol. Exp. Ther. 327(3), 746-759 (2008
34. Strieter R M, Burdick M D, Mesta, J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer. 42(6), 768-778 (2006
35. Del Rio L, Bennouna S, Salinas J, Denkers EY. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J. Immunol. 167, 6503-6509 (2001
36. Petering H, Gotze O, Kimmig D, Smolarski R, Kapp A, Elsner J. The biologic role of interleukin-8: Functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood 93, 694-702 (1999
37. Weber C, Kraemer S, Drechsler M, Lue H, Koenen RR, Kapurniotu A, Zernecke A, Bernhagen J. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc. Natl Acad. Sci. USA 105, 16278-16283 (2008
38. Boisvert WA, Rose DM, Johnson KA et al. Up-regulated expression of the CXCR2 ligand KC/GRO-A in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol. 168, 1385-1395 (2006
39. Li YT, Flores R, Yu A et al. Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer 117(1), 207-217 (2011
40. Yang G, Liu G, Xue F et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 16(15), 3875-3886 (2010
41. Park JY, Park KH, Bang S et al. CXCL5 overexpression is associated with late stage gastric cancer. J. Cancer Res. Clin. 133(11), 835-840 (2007
42. Kawanishi H, Matsui Y, Ito M et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin. Cancer Res. 14(9), 2579-2587 (2008
43. Kawanishi H, Matsui Y, Yamasaki et al. Cell culture proteome identifies CXCL1 as a secreted marker and mediator for the tumor invasion of bladder cancer. J. Urol. 177(4S), 260-260 (2007
44. Rubie C, Kollmar O, Frick VO et al. Differential CXC Receptor Expression in Colorectal Carcinomas. Scand. J. Immunol. 68(6), 635-644 (2008
45. Li AH, Varney M L, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7(10), 3298-3304 (2001
46. Erreni M, Bianchi P, Laghi L et al. Expression of chemokines and chemokine receptors in human colon cancer. In:Chemokines, PTA Book Series: Methods in Enzymology (Volume 460). Handel TM, Hamel DJ (Eds). Elsevier, Cambridge, MA, USA 105-121 (2009
47. Rubie C, Frick VO, Wagner M et al. ELR plus CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer 8, 178. (2008
48. Kollmar O, Junker B, Rupertus K, Menger MD, Schilling MK. Studies on MIP-2 and CXCR2 expression in a mouse model of extrahepatic colorectal metastasis. Eur. J. Surg. Oncol. 33(6), 803-811 (2007
49. Johrer K, Zelle-Rieser C, Perathoner A et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin. Cancer Res. 11(7), 2459-2465 (2005
50. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 175(8), 5351-5357 (2005
51. Wen Y, Giardina SF, Hamming D, Greenman J et al. GRO a is highly expressed in adenocarcinoma of the colon and down- regulates fibulin-1. Clin. Cancer Res. 12(20), 5951-5959 (2006
52. Wang, DZ, Wang HB Brown J et al. CXCL1 induced by prostaglandin E-2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203(4), 941-951 (2006
53. Ogatai H, Sekikawa A, Yamagishi H et al. GRO a promotes invasion of colorectal cancer cells. Oncol. Rep. 24(6), 1479-1486 (2010
54. Li A, King J, Moro A et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol. 178(3), 1340-1349 (2011
55. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int. J. Oncol. 22(4), 765-771 (2003
56. Matsuo Y, Ochi N, Sawai H et al. CXCL8/IL-8 and CXCL12/SDF-1 a co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 124(4), 853-861 (2009
57. Wolff HA, Rolke D Rave-Fraenk M et al. Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines. Radiat. Environ. Bioph. 50(1), 145-154. (2011
58. Oladipo O, Conlon S, O'Grady A et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Brit. J. Cancer 104(3), 480-487 (2011
59. Matsuo Y, Raimondo M, Woodward TA et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer 125(5), 1027-1037 (2009
60. Guha S, Bresalier R, Hoffman R, Burdick M, Strieter RM. CXC-chemokines/CXCR2 mediate a novel pathway of angiogenesis in pancreatic cancer. Proc. Am. Assoc. Canc. Res. 48, 1092-1093 (2007
61. Wente MN, Keane MP, Burdick, MD et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 241(2), 221-227 (2006
62. Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int. J. Cancer. 129(4), 847- 858 (2011
63. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 172(5) 2853-2860 (2004
64. Yanagawa J, Walser T, Zhu LX et al. The zinc-finger E-box-binding transcriptional repressor Snail promotes CXCR2 ligand dependent tumor progression in non-small cell lung cancer. Clin. Cancer Res. 15, 6820-6829 (2009
65. Sanchez J, Moldobaeva A, McClintock J, Jenkins J, Wagner E. The role of CXCR2 in systemic neovascularization of the mouse lung. J. Appl. Physiol. 103(2), 594-599 (2007
66. Nannuru KC, Sharma B, Varney ML et al. Malignant tumor and host tissue CXCR2 expression promotes mammary tumor growth, angiogenesis, and progression. Clin. Exp. Metastasis. 28(2), 200(2011
67. Singh S, Sadanandam A, Nannuru KC et al. Small-molecule antagonists for cxcr2 and cxcr1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin. Cancer Res. 15(7), 2380-2386 (2009
68. Singh S, Varney M, Singh RK. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69(2), 411-415 (2009
69. Varney ML, Li A, Singh S et al. Small molecule antagonists for CXCR1 and CXCR2 inhibit human colon cancer metastasis by decreasing angiogenesis and enhancing apoptosis. Proc. Am. Assoc. Canc. Res. 48, 1330-1331 (2007
70. Shen H, Schuster R, Lu B, Waltz SE, Lentsch AB. Critical and opposing roles of the chemolkine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66(16), 1721-1728 (2006
71. Li A, Cheng XJ, Moro A et al. CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth. Trans. Oncol. 4(1), 20-28 (2011
72. Naldini A, Filippi I, Miglietta D et al. Interleukin-1 b regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1 a. Eur. J. Cancer 46(18), 3400-3408 (2010
73. Agarwal A, Tressel SL, Kaimal R et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy. Cancer Res. 70(14), 5880-5890 (2010
74. Ning Y, Manegold PC, Hong, YK et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer. 128(9), 2038-2049 (2011
75. Yang G, Liu G, Xue F et al. CXCR2 is required for human ovarian cancer growth through increased cell-cycle progression and enhanced angiogenesis. Clin. Cancer Res. 16, 3875-3886 (2010
76. Sharma B, Nawandar D, Varney ML et al. Enhancing efficacy of drugs by targeting CXCR2 receptor signaling for the treatment of malignant breast cancer. Proc. Am. Assoc. Canc. Res. 51, 1325 (2010
77. Singh S, Nannuru KC, Sadanandam A et al. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Brit. J. Cancer. 100(10), 1638-1646 (2009
78. Singh S, Singh AP, Sharma B et al. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol. 6(1), 111-116 (2010
79. Singh S, Sadanandam A, Varney ML et al. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int. J. Cancer 26(2) 328-336 (2010
80. Sharma B, Singh S, Varney, ML et al. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin. Ther. Targ. 14(4), 435-442 (2010
81. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts J. Clin. Invest. 120(2), 485-497 (2010
82. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4), 1302-1313 (2009
83. Bolitho C, Hahn MA, Baxter RC, Marsh DJ. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr. Relat. Cancer 17(4), 929-940 (2010
84. Donnelly LE, Barnes PJ. Chemokine receptor CXCR2 antagonism to prevent airways inflammation. Drugs Fut. 36(6), 465-472 (2011
85. Asadollahi T, Dadfarni S, Shabani AMH et al. QSAR models for CXCR2 Receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the pls linear regression method and design of the new compounds using in silico virtual screening. Molecules 16(3), 1928-1955 (2011
86. Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 308(1), 91-99 (2011
87. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett. 300(2), 180-188(2010
88. Min SH, Wang YF, Gonsiorek W et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem. Biophys. Res. Commun. 391(1), 1080-1086 (2010
89. Younong-Yu Y, Dwyer MP, Chao J et al. Synthesis and structure-Activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett. 18(1), 1318-1322 (2008
90. Purakkattle B, Taveras A, Yu Y et al. 3,4-diamino-2,5-Thiadiazole-1- oxides as potent CXCR2/CXCR1 antagonists. Bioorg. Med. Chem. Lett. 18(1), 228-231 (2008
91. Pan, JD, Burdick MD, Belperio JA et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis J. Immunol. 176(3), 1456-1464 (2006
92. Andersson A, Srivastava MK, Harris-White M et al. Role of CXCR3 Ligands in IL-7/IL-7R a-Fc-mediated antitumor activity in lung cancer. Clin. Cancer Res. 17(11) 3660-3672 (2011
93. Shin SY, Nam J-S, Lim Y, Lee YH. TNF a-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokine. J. Biol. Chem. 285(40), 30731-30740 (2010
94. Dorsey R, Kundu N, Yang QY et al. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-g. Cancer Res. 62(9) 2606-2610 (2002
95. Groom JR, Luster AD. CXCR3 ligands: Redundant, collaborative and antagonistic functions Immunol. Cell Biol. 89(2) 207-215 (2011
96. Dengel LT, Norrod AG, Gregory, BL et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. 33(9), 965-974 (2010
97. Antonelli A, Ferrari SM, Fallahi P et al. Dysregulation of secretion of CXC a-chemokine CXCL10 in papillary thyroid cancer: Modulation by peroxisome proliferator-Activated receptor-g agonists. Endocr. Relat. Cancer. 16(4), 1299-1311 (2009
98. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-A 2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8(+) effector T cells. J. Leukocyte Biol. 71(4) 669-676 (2002
99. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S. CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J. Biol. Chem. 285(47), 36842-36848 (2010
100. Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J. Am. Soc. Nephrol. 19(12), 2437-2446 (2008
101. Datta D, Flaxenburg JA, Laxmanan S et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res. 66(19), 9509-9518 (2006
102. Gacci M, Serni S, Lapini A et al. CXCR3-B Expression correlates with tumor necrosis extension in renal cell carcinoma. J. Urol. 181(2), 843-848 (2009
103. Petrai I, Rombouts K, Lasagni L et al. Activation of p38 (MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int. J. Biochem. Cell B. 40(9), 1764-1774 (2008
104. Lasagni L, Francalanci M, Annunziato F et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197(11), 1537-1549 (2003
105. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J. Immunol. 173(10), 6234-6240 (2004
106. Soejima K, Rollins BJ. A functional IFN-g-inducible protein-10/CXCL10- specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J. Immunol. 167(11), 6576-6582 (2001
107. Campanella GSV, Colvin R A, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS ONE 5(9), e12700 (2010
108. Naumann U, Cameroni E, Pruenster M et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 5(2), e9175 (2010
109. Ohtani H , Jin Z, Takegawa S et al. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J. Pathol. 217(1), 21-31 (2009
110. Ohtani H, Yoshie O. Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers. Virchows Ach. 456(6), 615-623 (2010
111. Sakuyama R, Aruga A, Kuramochi H et al. The analysis of CCR4+/CXCR3+ cell ratio in gastrointestinal cancer patients receiving chemotherapy or immunotherapy. Cancer Chemother. 35(12), 2259-2261(2008
112. Winter D, Moser J, Kriehuber E et al. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J. Immunol. 179(6), 4272-4282 (2007
113. Chen P, Yang LL, Yang HS et al. Synergistic antitumor effect of CXCL10 with hyperthermia J. Cancer Res. Clin. 134(6), 679-687 (2008
114. Yang JM, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9(6), 846-855 (2004
115. Andersson A, Yang S-C, Huang M et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J. Immunol. 182(11) 6951-6958 (2009
116. Mlecnik B, Tosolini M, Charoentong P et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4), 1429-1440 (2010
117. Harlin H, Meng Y, Peterson AC et al. chemokine expression in melanoma metastases associated with CD8+ T-Cell recruitment. Cancer Res. 69(7), 3077-3085 (2009
118. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol. Biol. Rep. 37(6), 3029-3036 (2010
119. Nagpal ML, Davis Jeffrey, Lin Tu. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biol. Mol. Basis Dis. 1762(9), 811-818 (2006
120. Antonicelli F, Lorin J, Kurdykowski S et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Brit. J. Dermatol. 164(4), 720-728 (2011
121. Yang LL, Chen P, Luo S et al. CXC-chemokine-ligand-10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-Angiogenic and antiviral activity. Biotechnol. Appl. Bioc. 53, 209-216 (2009
122. Arenberg DA, White ES, Burdick MD, Strom SRB, Strieter RM. Improved survival in tumor-bearing SCID mice treated with interferon-g-inducible protein 10 (IP-10/CXCL10). Cancer Immunol. Immun. 50(10), 533-538 (2001
123. Ruehlmann JM, Xiang R, Niethammer AG et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61(23), 8498-8503 (2001
124. Wang YQ, Wada A, Ugai SI, Tagawa M. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. Oncol. Rep. 10(4), 909-913 (2003
125. Walser TC, Ma X, Kundu N, Dorsey R, Goloubeva O, Fulton AM. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine mig (CXCL9) in a murine model. J. Immunother. 30(5), 490-498 (2007
126. Li G, Tian L, Hou JM et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin. Cancer Res. 11(11) 4217-4224 (2005
127. Zhang R, Tian L, Chen LJ et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther. 13(17), 1263-1271 (2006
128. Hensbergen PJ, Wijnands PG, Schreurs MWJ et al. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J. Immunother. 28(4), 343-351 (2005
129. Berencsi K, Meropol NJ, Hoffman JP et al. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol. Immun. 56(3), 359-370 (2007
130. Amatschek S, Lucas R, Eger A et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Brit. J. Cancer 104(3), 469-479 (2011
131. Li L, Chen J, Lu Z et al. Significance of chemokine receptor CXCR3 expression in breast cancer. J. Pathol. 40(2), 85-88 (2011
132. Ma X, Norsworthy K, Kundu N et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther. 80(3), 490-498 (2009
133. Goldberg-Bittman L, Neumark E, Sagi-Assif O et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett. 92(1-2), 171-178 (2004
134. Walser TC, Rifat S, Ma X et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66(15), 7701-7707 (2006
135. Liu C, Luo D, Reynolds BA et al. Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 32(2), 129-137 (2011
136. Maru SV, Holloway KA, Flynn G et al. Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation. J. Neuroimmunol. 199(1-2), 35-45 (2008
137. Zipin-Roitman A, Meshel T, Sagi-Assif O et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 67(7), 3396-3405 (2007
138. Kawada K, Hosogi H, Sonoshita M et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26(32), 4679-4688 (2007
139. Wu Q, Wells A. Promotion of prostate cancer cell migration and invasion via CXCR3 signaling. Proc. Am. Assoc. Canc. Res. 51, 1261 (2010
140. Reckamp KL, Figlin RA, Moldawer N et al. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J. Immunother. 30(4) 417-424 (2007
141. Klatte T, Seligso, DB, Leppert JT et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J. Urol. 179(1), 61-66 (2008
142. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: Correlation with clinicopathological prognostic factors. J. Clin. Pathol. 60(6) 596-599 (2007
143. Haqq C, Nosrati M, Sudilovsky D et al. The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102(17) 6092-6097 (2005
144. Kawada K, Sonoshita M, Sakashita H et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 64(11), 4010-4017 (2004
145. Pellegrino A, Antonaci F, Russo F et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 207(2), 221-227 (2003
146. Giuliani N, Bonomini S, Romagnani P et al. CXCR3 and its binding chemokines in myeloma cells: Expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11), 1489-1497 (2006
147. Goldberg-Bittman L, Sagi-Assif O, Meshel T et al. Cellular characteristics of neuroblastoma cells: Regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 29(3), 105-117 (2005
148. Wolff HA, Rolke D, Rave-Frank M et al. Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines. Radiat. Environ. Biophys. 50(1) 145-154 (2011
149. Ginos MA, Page GP, Michalowicz BS et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64(1), 55-63 (2004
150. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM.The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 95(2), 627-632 (2000
151. Yu Y, Merlino G. Roles for aberrant CXCR3 signaling in basal cell carcinoma A case for dual activity. Am. J. Pathol. 176(5), 2088-2091 (2010
152. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee K J. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas Am. J. Pathol. 176(5), 2435-2446 (2010
153. Maekawa S, Iwasaki A, Shirakusa T et al. Association between the expression of chemokine receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma. Oncol. Rep. 19(6), 1461-1468 (2008
154. Kim SH, Anilkumar GN, Zawacki LG et al. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold Bioorg. Med. Chem. Letts. 21(23), 6982-6986 (2011
155. Pease JE, Horuk R. Chemokine receptor antagonists: Part 2. Expert Opin. Ther. Pat. 19(2), 199-221 (2009
156. Wijtmans M, Verzijl D, Bergmans S et al. CXCR3 antagonists: Quaternary ammonium salts equipped with biphenyl- And polycycloaliphatic-Anchors. Bioorg. Med. Chem. 19(11), 3384-3393 (2011
157. Wijtmans M, Verzijl D, Leurs R de Esch IJP, Smit MJ. Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 3(6) 861-872 (2008
158. Pradelli E, Karimdjee-Soilihi B, Michiels F et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int. J. Cancer. 125(11), 2586-2594 (2009
159. Cambien B, Karimdjee BF, Richard-Fiardo P et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Brit. J. Cancer. 100(11), 1755-1764 (2009
160. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 Axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Design. 16(35), 3903-3920 (2010
161. Furusato BM, Ahmed U, Mathias R, Johng S. CXCR4 and cancer. Pathol. Int. 60(7), 497-505 (2010
162. Rubin JB. Chemokine signaling in cancer: One hump or two? Semin. Cancer Biol. 19(2), 116-122 (2009
163. Sun XC, Guangcun H, Mingang Z et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metast. Rev. 29(4), 709-722 (2010
164. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev. Anticancer Ther. 11(4), 621-630 (2011
165. Gangadhar, T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol. Ther. 9(6), 409-416 (2010
166. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: Perspectives in SCLC. Expert Opin. Investig. Drugs. 18(4), 481-490 (2009
167. Terasaki M, Terasaki M, Sugita Y et al. CXCL12/CXCR4 signaling in malignant brain tumors: A potential pharmacological therapeutic target. Brain Tumor Pathol. 28(2), 89-97 (2011
168. Shim H, Oishi S, Fujii N. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin. Cancer Biol. 19(2), 123-134 (2009
169. Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 23(1), 43-52 (2009
170. Hinton CV. Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metast. 27(2), 97-105 (2010
171. Clezardin P. Therapeutic targets for bone metastases in breast cancer Breast Cancer Res. 13(2), 207-216 (2011
172. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-Targeted therapy for metastatic breast cancer. Nat. Rev. Clin. Oncol. 7(11), 641-651 (2010
173. Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: A potential therapeutic target for bone metastases? Curr. Pharm. Deign. 16(11), 1284-1290 (2010
174. Smith MC, Luker KE, Garbow JR et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64(23), 8604-8612 (2004
175. Kajiyama, H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1a/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 122 (1), 91-99 (2008
176. Kim SY, Lee CH, Midura BV et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metast. 25(3) 201-211 (2008
177. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65(3), 967-971 (2005
178. Liang Z, Wu T, Lou H et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64(12), 4302-4308 (2004
179. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: From bench to bedside. Clin. Cancer Res. 14(24), 7975-7980 (2008
180. Porvasnik S, Sakamoto N, Kusmartsev S et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 69(13), 1460-1469 (2009
181. Hassan S, Buchanan M, Jahan K et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer. 129(1), 225-232 (2011
182. Huang EH, Singh B, Cristofanilli M et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res. 155(2), 231-236 (2009
183. Singh B, Cook KR, Martin C et al. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin. Exp. Metast. 27(4), 27, 233-240 (2010
184. Richert MM, Vaidya KS, Mills CN et al. Inhibition of CXCR4 by CTCE-9908
185. Jantunen E. Novel strategies for blood stem cell mobilization: Special focus on plerixafor. Expert Opin. Biol. Ther. 11(9), 1241-1248 (2011
186. Jenkinson S, Thomson M, McCoy D et al. Blockade of X4-Tropic HIV-1 cellular entry by gsk812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob. Agents Chemother. 54(2), 817-824 (2010
187. Moyle G, DeJesus E, Boffito M et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-Tropic HIV type 1. Clin. Infect. Dis. 48(6), 798-805 (2009
188. Lefrancois M, Lefebvre M-R, Saint-Onge G et al. Agonists for the chemokine receptor CXCR4. Med. Chem. Lett. 2(8), 597-602 (2011
189. Tchernychev B, Ren Y, Sachdev P et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc. Natl Acad. Sci. USA 107(51), 22255-22259 (2010
190. Wu B, Chien EY, Mol CD, Fenalti et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007), 1066-1071 (2010
191. Yau, C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12(5), R85 (2010
192. Panse J, Friedrichs K, Marx A et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br. J. Cancer 99(6), 930-938 (2008
193. Del Grosso F, Coco S, Scaruffi P et al. Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and schwannian stromal cells in neuroblastic tumors. Mol. Cancer Res. 9(7), 815-823 (2011
194. Airoldi I, Cocco C Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol. Immunother. 57(4), 541-548 (2008
195. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res. 66(19), 9576-9582 (2006
196. Henger A, Kretzler M, Doran P et al. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int. 65(3), 904-917 (2004
197. Barbieri F, Bajetto A, Porcile C et al. CXC receptor and chemokine expression in human meningioma - SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation. Ann. NY Acad. Sci. 1090, 332-343 (2006
198. Pandruvada SNM, Yuvaraj S, Liu X et al. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int. J. Cancer. 126(10), 2319-2329 (2010
199. Muller A, Sonkoly E, Eulert C et al. Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int. J. Cancer. 118(9), 2147-2157 (2006
200. Yuvaraj S, Griffin AC, Sundaram K, Kirkwood KL, Norris JS, Reddy SA. Novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol. Cancer Res. 7(8), 1399-1407 (2009
201. Wedel SA, Raditchev IN, Jones J et al. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol. Med Report 1(2), 257-262 (2008
202. Singh S, Singh R Singh U et al. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int. J. Cancer 125(10), 2288-2295 (2009
203. Singh S, Singh R, Sharma PK et al. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 283(1), 29-35 (2009
204. Fischer L, Korfel A, Pfeiffer S et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin. Cancer Res. 15(19), 5968-5973 (2009
205. Engl T, Relja B, Blumenberg C et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci. 78(16), 1784-1793 (2005
206. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 44(4), 311-319 (2011
207. El Haibi CP, Sharma PK, Singh R et al. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol. Cancer. 9, 85. (2010
208. Schramme A, Abdel-Bakky MS, Kaempfer-Kolb N et al. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells Biochem. Biophys. Res. Commun. 370(2) 311-316 (2008
209. Scheller J, Chalaris A, Garbers C et al. ADAM17: A molecular switch to control inflammation and tissue regeneration Trends Immunol. 32(8), 380-387 (2011
210. Saftig P, Reiss KA. ADAM10 and ADAM17: Novel drug targets with therapeutic potential? Eur. J. Cell Biol. 90(6-7), 527-535 (2011
211. Darash-Yahana M, Gillespie JW, Hewitt SM et al. CXCL16 and CXCR6 may promote inflammation-Associated cancer growth through autocrine effects on cancer cells and paracrine effects on leukocytes. Proc. Am. Assoc. Canc. Res. 48, 1212 (2007
212. Gutwein P, Schramme A, Sinke N et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur. J. Cancer. 45(3), 478-489 (2009
213. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98(11), 1652-1658 (2007
214. Hojo S, Koizumi K, Tsuneyama K et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 67(10), 4725-4731 (2007
215. Lu Y, Wang J, Xu Y et al. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol. Cancer Res. 6(4), 546-554 (2008
216. Matsumura S, Demaria S. Upregulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat. Res. 173(4), 418-425 (2010
217. Satoko WB, Kawashima N, Braunstein S et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181(5), 3099-3107 (2008
218. Parsonage G., Machado LR., Hui JW et al. CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. Am. J. Pathol. 180(3), 1215-1222 (2012
219. Darash-Yahana M., Gillespie JW, Hewitt SM et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-Associated cancers. PLoS ONE 4(8), e6695 (2009
220. Matsumura S, Wang B, Kawashima N et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181 (5), 3099-3107 (2008
221. Choi DY, Hong R, Lim SC, Kee KH, Suh CH, Lee M. Prognostic implications of the expression of CXCL16 in breast carcinoma. Korean J. Pathol. 45(1), 15-20 (2011
222. Wang B, Badura M, He C et al. CXCR6 and CXCL16 are expressed by breast cancer cells and may play a dual role in tumor progression. Presented at: 29th Annual San Antonio Breast Cancer Symposium, 14-18 December 2006.
223. Lin S, Sun L, Hu J et al. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett. 279(1), 108-117 (2009
224. Ou DL, Chen CL, Lin SB, Hsu CH, Lin LI. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J. Pathol. 210(3), 363-373 (2006
225. Chen CL, Tu H-J, Wu TJ, Cheng AL, H CH. CXCR4 and CXCR6 chemokine receptor-mediated migration and invasion of nasopharyngeal cancer cells are inhibited by Src inhibitors. Proc. Am. Assoc. Canc. Res. 50, 527-528 (2009
226. Gaida MM, Guenther F, Wagner C et al. Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin. Exp. Immunol. 154(2), 216-223 (2008
227. Wente MN, Gaida MM, Mayer C et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int. J. Oncol. 33(2), 297-308 (2008
228. Lu Yi, Chen Q, Wang J et al. MCP-1/CCR2 and CXCL16/CXCR6 as novel biomarkers to predict cancer skeletal metastases. Proc. Am. Assoc. Canc. Res. Annual Meeting, 50, 247-248 (2009
229. Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res. 68(24), 10367-10376 (2008
230. Singh PK, Singh R, Eaton JW et al. Expression and functional role of CXCR6 in prostate cancer. Proc. Am. Assoc. Canc. Res. 50, 547-548 (2009
231. Ha HK, Lee W, Park HJ et al. Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol. Med. Report 4(3), 419-424 (2011
232. Hu W, Zhen X, Xiong B et al. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 99(7), 1362-1369 (2008
233. Seidl H, Richtig E, Tilz H et al. Profiles of chemokine receptors in melanocytic lesions: De novo expression of CXCR6 in melanoma. Human Pathol. 38(5), 768-780 (2007
234. Taghizadeh R, Noh M, HuhY et al. CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS ONE 5(12), e15183 (2010
235. Qin Y, Verdegaal EME, Siderius M et al. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: The constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res. 24(1), 207-218 (2011
236. Darash-Yahana M, Gillespie JW, Foley JF et al. The transmembrane chemokine CXCL16 is highly expressed in cancers of the prostate, colon, breast, ovary, and brain. Proc. Am. Assoc. Cancer Res. Abstract 6017 (2005
237. Guo L, Cui ZM, Zhang J, Huang Y. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. J. Cancer. 30(5), 336-343 (2011
238. McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma. Curr. Opin. Urol. 19(5), 441-446 (2009
239. Diegelmann J, Seiderer J, Niess JH et al. Expression and regulation of the chemokine CXCL16 in crohn's disease and models of intestinal inflammation. Inflamm. Bowel Dis. 16(11), 1871-1881 (2010
240. Wagsater D, Dimberg J. Expression of chemokine receptor CXCR6 in human colorectal adenocarcinomas. Anticancer Res. 24(6), 3711-3714 (2004
241. Liu Y, Li R, Li J et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J. Exp. Clin. Cancer Res. 29(1), 16-25 (2010
242. Kodama J, Hasengaowa KT, Seki N et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Annu. Oncol. 18(1), 70-76 (2006
243. Muller M. Carter S, Hofer MJ et al. The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - A tale of conflict and conundrum. Neuropath. Appl. Neuro. 36(5), 368-387 (2010).